Live Signals
Signals ScoreSignals Score (0–100) blends the three technical signals — MA, RSI and MACD — where BUY = 100, HOLD/NEUTRAL = 50, SELL = 0.
Each signal is weighted by its own historical BUY hit-rate for this ticker (a signal that has been right more often counts for more). Hit-rates from only a handful of past signals are pulled toward equal weight, so a small, noisy sample can't swing the score.
(32.50)
(36.10)
(15.70)
3 of 3 frames agree
Sessions where price opened above the prior high or below the prior low
| Date | Type | Gap % | Prev Close | Open | Filled? |
|---|---|---|---|---|---|
| 2026-11-17 | Gap Down | -0.52% | $67.10 | $66.75 | Filled |
| 2026-11-06 | Gap Down | -0.52% | $68.71 | $68.35 | Filled |
| 2026-10-30 | Gap Up | +3.14% | $66.20 | $68.28 | Filled |
| 2026-10-29 | Gap Up | +0.98% | $66.28 | $66.93 | Filled |
| 2026-10-20 | Gap Up | +0.53% | $62.68 | $63.01 | Open |
| 2026-10-15 | Gap Up |
Candlestick patterns identified in recent price action
Bearish Engulfing
2026-11-12
A red candle fully engulfs the prior green candle. Sellers overwhelmed buyers in a single session — strong short-term reversal signal.
Support
Resistance
Stockasthics is an educational tool only. Nothing on this page constitutes financial advice. All signals, scores, and data are for informational and learning purposes only.
weekly
Signals from weekly candles smooth out daily noise and reveal the true intermediate trend. More reliable for direction. A BUY on the weekly carries more conviction than a daily BUY alone.
| +1.15% |
| $60.99 |
| $61.69 |
| Open |
| 2026-09-25 | Gap Up | +0.52% | $57.95 | $58.25 | Filled |
| 2026-09-11 | Gap Down | -1.17% | $57.43 | $56.76 | Filled |
EXEL: +31.9% vs SPY: -2.9% → RS: +34.9% Relative Strength = stock return minus index return over the same window. Positive = outperforming the market. Academic research (Jegadeesh & Titman 1993) shows stocks with strong relative momentum tend to keep outperforming for 3–12 months. >+5% → BUY | <-5% → SELL | in between → NEUTRAL
Relative Strength vs SPY
Measures how this stock has performed relative to the S&P 500. Persistent outperformance signals institutional sponsorship and sector leadership. Underperformance warns of rotation out of the stock, even in a rising market.
Exelixis, Inc., an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat specific forms of advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan. It develops zanzalintinib, a novel, potent oral inhibitor of kinases, including the TAM kinases, MET, and VEGF receptors; XL309, a small molecule inhibitor of USP1, a synthetic lethal target in the context of BRCA-mutated tumors; XB010, an antibody-drug conjugates (ADC) consisting of a MMAE payload conjugated to a monoclonal antibody targeting the tumor antigen 5T4; XB628, a first-in-class bispecific antibody that targets programmed cell death ligand 1and natural killer cell receptor group 2A; and XB371, a next-generation tissue factor targeting ADC with a topoisomerase inhibitor payload. It has research collaborations and license agreements with Ipsen Pharma SAS; Takeda Pharmaceutical Company Ltd.; F. Hoffmann-La Roche Ltd.; Catalent, Inc.; Iconic Therapeutics, Inc.; Adagene Inc.; Invenra, Inc.; Genentech, Inc.; Bristol-Myers Squibb Company; and Daiichi Sankyo Company, Limited, as well as business development activities and other collaborations. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was incorporated in 1994 and is headquartered in Alameda, California.
Official website ↗5-year in-sample backtest of the combined MA/RSI/MACD signal
| Signal | # Signals | Hit Rate 5d | Hit Rate 10d | Hit Rate 20d | Avg Return 5d | Avg Return 10d | Avg Return 20d |
|---|---|---|---|---|---|---|---|
| BUY | 766 | 53.8% | 55.6% | 56.8% | +0.46% | +1.13% | +1.63% |
| SELL | 202 | 44.6% | 39.6% | 26.7% | +0.63% | +1.47% | +4.01% |
Hit rate = % of BUY signals where price was higher (or SELL signals where it was lower) at the given horizon. Does not account for transaction costs. In-sample only — not a prediction of future performance.
Last 20 trading days
| Date | Close | MA | RSI | MACD | Combined |
|---|---|---|---|---|---|
| 2026-10-23 | $64.53 | BUY | HOLD | BUY | BUY |
| 2026-10-26 | $65.11 | BUY | HOLD | BUY | BUY |
| 2026-10-27 | $65.35 | BUY | HOLD | BUY | BUY |
| 2026-10-28 | $66.28 | BUY | HOLD | BUY | BUY |
| 2026-10-29 | $66.20 | BUY | HOLD | BUY | BUY |
| 2026-10-30 | $69.39 | BUY | HOLD | BUY | BUY |
| 2026-11-02 | $70.13 | BUY | HOLD | BUY | BUY |
| 2026-11-03 | $72.31 | BUY | HOLD | BUY | BUY |
| 2026-11-04 | $72.75 | BUY | HOLD | BUY | BUY |
| 2026-11-05 | $68.71 | BUY | HOLD | BUY | BUY |
| 2026-11-06 | $69.57 | BUY | HOLD | BUY | BUY |
| 2026-11-09 | $71.74 | BUY | HOLD | BUY | BUY |
| 2026-11-10 | $70.58 | BUY | HOLD | BUY | BUY |
| 2026-11-11 | $70.70 | BUY | HOLD | BUY | BUY |
| 2026-11-12 | $69.84 | BUY | HOLD | HOLD | BUY |
| 2026-11-13 | $69.00 | BUY | HOLD | HOLD | BUY |
| 2026-11-16 | $67.10 | BUY | HOLD | HOLD | BUY |
| 2026-11-17 | $68.50 | BUY | HOLD | HOLD | BUY |
| 2026-11-18 | $68.29 | BUY | HOLD | HOLD | BUY |
| 2026-11-19 | $65.83 | BUY | BUY | HOLD | BUY |